Panelists discuss how NICHE-2 trial updates offer valuable insights into the role of minimal residual disease assessment in guiding neoadjuvant immunotherapy for colorectal cancer patients.

Panelists discuss how updates from the POD1UM-303/InterAACT2 trial presented at European Society for Medical Oncology Congress (ESMO) 2024 shed light on retifanlimab’s potential role in advancing ...

Panelists discuss how LEAP-012 trial results show promising progression-free survival, while anticipating further data on overall survival outcomes.

The approval of inavolisib is supported by findings from the phase 3 INAVO120 study evaluating the agent plus palbociclib and ...

According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...

Eric Cheung, DO, Targeted Oncology’s second 2024 Oncology Icon, discussed his journey in oncology, advances in treatment, and ...

Amy Selly, CNP, AOCNP, discusses how physicians can support their patients' survivorship journeys.

Support is essential for cancer survivors. By connecting with others who understand their experiences, cancer survivors can find strength, hope, and a sense of community.

Cancer survivors often face a unique set of challenges that can impact their physical, emotional, and social well-being. Some of the most common challenges include physical like fatigue or pain, ...

Cancer survivorship is a complex concept that can be defined in various ways, depending on the context and perspective. Some common approaches include time-based definitions, state-based definitions ...

The first patient with advanced gastric and gastroesophageal cancer has been dosed in a trial combining PT886 with ...

Samer A. Al'Hadidi, MD, MS, reviewed the benefits of cilta-cel in the subgroup analysis of CARTITUDE-4 in patients with ...